Quietly, the German pharmaceutical and tech firm has emerged as a major international player in Israel
With more than 300 employees at four sites throughout Israel, Merck KgaA, a multifaceted chemical and technology company, has quietly emerged as one of the major multinational firms with a significant presence in Israel.
The company announced this week that it was furthering its stake in Israeli tech by signing a new framework agreement with the Weizmann Institute to research new solutions in the area of biotechnology and cancer research.
“We have focused our healthcare research activities on the highly promising fields of immuno-oncology, immunology and oncology, as we’re striving to deliver new solutions to respond to unmet medical needs,” said Stefan Oschmann, deputy CEO and vice chairman of the executive board of Merck. “We’re excited that the new framework agreement will cover the first two of these three areas, and we are already looking forward to the proposals of the distinguished Weizmann scientists.”
As part of the new framework agreement, Merck will fund each of the two research areas with up to € 1 million per year over the initial three-year period.
Merck (there are actually two separate companies called Merck; Merck KgaA, which operates everywhere except the US and Canada, where an independent company called Merck and Co. operates) is no stranger to the Weizmann Institute. Merck is best known for its drugs, but less well known is the strong connection the company — established in 1688 — has with Israel, where it has been active since 1978.
On a recent visit to Israel, Karl-Ludwig Kley, CEO of Merck KgaA, said that “15 percent of our products have an Israeli background, many of them researched at the Weizmann Institute. We have strong working relationships to develop products with all of Israel’s research institutes.